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Abstract
Clostridium butyricum MIYAIRI 588 (CBM 588) is a nonpathogenic, anaerobic, gram-positive bacillus characterized by the
production of short-chain fatty acids, including butyrate. The safety and tolerance of CBM 588 was investigated as a feed
additive for broiler chickens, weaned piglets, and turkeys. CBM 588 administered to broilers at doses up to 5 107 CFU/g
feed for 42 days produced no detrimental effects on zootechnical performance, natural mortality, hematology, or bio-
chemical parameters. Piglets receiving CBM 588 at doses up to 5  107 CFU/g feed for 42 days showed no significant
differences from controls in zootechnical performance, mortality, or morbidity. Finally, CBM 588 administered to turkeys
at doses up to 2.5  107 CFU/g feed for 84 days produced no detrimental effects on zootechnical performance,
hematology, or biochemical parameters. Some improvements in zootechnical performance were seen with CBM 588,
including improved average daily gain (ADG) and feed conversion for broilers from days 1 to 21 as well as final body weight
and overall ADG for turkeys. Overall, CBM 588 administered in feed at dose up to 5 107 CFU/g (broilers and piglets) or
2.5 107 CFU/g (turkeys) was shown to be safe and well-tolerated in all tested animals and may provide some nutritional
benefit when added to standard commercial feed.
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Introduction
Clostridium butyricum is a gram-positive bacillus found
frequently in the environment as well as in the gastrointest-
inal tract of animals. C. butyricum MIYAIRI 588 (CBM
588) is a strain of C. butyricum that is differentiated from
other strains using KM1 bacteriophage susceptibility. This
nongenetically modified, obligate anaerobe lacks patho-
genicity and toxigenicity, as confirmed by the following:
(1) lack of transmissible antibiotic resistance, (2) absence
of plasmids with mobile genetic elements, (3) absence of
clostridial toxin genes and products (botulinum neurotoxins
A, B, E, and F, genes encoding for Clostridium perfringens
toxins , , "), (4) absence of pathogenic markers via
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genomic analyses, and (5) lack of hemolytic potential.1
The safety of CBM 588 has been demonstrated in a
series of studies, including genotoxicity, acute toxicity
in rats, 5-week repeat oral dose toxicity in dogs, sub-
chronic toxicity in rats, and two-generation reproduc-
tion/teratology study in mice.1–4
Microbial fermentation of carbohydrates in the gastro-
intestinal tract results in the production of short-chain fatty
acids (SCFAs), including acetate, propionate, and butyrate.
SCFAs are an important energy source for the animal and
are readily used for tissue maintenance, growth, and lipo-
genesis.5–7 Both C. butyricum in general8–10 and CBM 588
specifically11,12 have been shown to produce high levels of
butyrate. CBM 588 has also been shown to increase the
relative abundance of other SCFAs-producing gut bacteria,
including Bifidobacterium, Coprococcus, and Bacteroides
species.13 The administration of CBM 588 to rats was
shown to significantly increase butyrate, propionate, and
acetate concentrations in the cecum.14
Butyrate can be metabolized by nearly all tissues in
the body and serves as the preferred energy source for
colonocytes to stimulate their multiplication and
differentiation.5,7,15–18 As such, butyrate production
plays an important role in the maintenance of gut
health.16,19 SCFAs promote the absorption of water and
sodium from the large bowel, with butyrate having the
strongest effect.18 This is achieved by the formation of
SCFA gradients across the colonic epithelium, resulting
in transient intracellular acidification and increased active
transport of sodium and chloride into colonocytes.20–22
These physiological and nutritional effects have been
well documented in livestock animals, including pigs and
poultry.23,24
As a producer of butyrate, CBM 588 is intended for use
as an additive to enhance the nutritional value of feed for
chickens, piglets, and turkeys. This manuscript reports the
safety and tolerance of CBM 588 as a feed additive in
these animals.
Materials and methods
Organic acid production
The production of organic acids by CBM 588, C. butyri-
cum, and other bacteria was analyzed as previously
reported.12 All bacteria were cultured using Gifu Anaerobic
Medium broth at 37C for 48 h under anaerobic conditions
prior to analysis by high-performance liquid
chromatography.
Study design
Studies were performed to evaluate the tolerance of CBM
588 in broilers, piglets, and turkeys. Studies followed the
principles of the Guidelines on Good Clinical Practice for
Clinical Trials for Registration of Veterinary Medicinal
Products,25 European Union (EU) Principles for Animal
Care and Experimentation, and appropriate quality
standards as indicated by the European Food Safety
Authority.26 Tolerance doses were based on the intended
commercial doses in the EU, which are 5 105 CFU/g feed
for broilers and piglets and 1.25  105 CFU/g feed for
turkeys. The maximum tested dose was set to 100 the
intended dose for all studies. However, the dose intended
for use in turkeys was halved before execution of the study,
resulting in a maximum tested dose of 200 the final com-
mercial dose.
Broiler tolerance study, IRTA B-307
A total of 384 Ross 308 broiler chickens (1-day old) were
used and sexed at the hatchery. Breeder flock history and
vaccination history of the broilers were recorded. Proce-
dures were in agreement with the Ethical Committee for
Animal Care and Experimentation of IRTA.
The study was carried out in the broiler cage unit of the
IRTA experimental facilities, Valls, Catalunya, Spain.
Birds were kept in a clean room and housed in 96 cages,
each having an area of 0.305 m2 and a height of 37 cm.
Stocking density was approximately 13 chicks/m2, similar
to that practiced commercially. The room was supplied
with artificial, programmable lights, automated aerotherm
heating, and forced ventilation. Temperature inside the
room was set at 33–35C at study start and decreased by
3C each week. From day 28 until study end, the tempera-
ture was set at 22C. The lighting program was 23-h light
and 1-h dark during each 24-h period. The study terminated
when birds were 43 days of age.
The study design was blocked with four dietary treat-
ments (described subsequently). Each treatment was
administered to 24 cages, with each cage containing four
broilers of the same sex. Thus, 12 cages of males and
12 cages of females were used per treatment (n ¼ 48/
sex/group). Replicates (cages) were spatially allocated
within the house to minimize potential cross-
contamination between treatments. Empty cages were
used to separate blocks of treatment groups. To further
safeguard against cross-contamination, personnel
handled control animals first, followed by treated ani-
mals from low to high dose.
All animals received starter diet from days 1 to 21 and
finisher diet from days 22 to 43. Diets are described in
detail in Supplementary Table 1. The control group
received the basal diet containing 10 g/kg starch. This
starch content was replaced with CBM 588 powder as nec-
essary (up to 10 g/kg) to reach the desired experimental
concentration for the treatment groups. The test concentra-
tions of CBM 588 were 5  105, 5  106, and 5  107
CFU/g feed. Feed analysis to ensure correct nutrient and
CBM 588 content was conducted using AOAC methods on
the day of manufacture. Diets were formulated without
antimicrobials other than coccidiostats. Mash feed and
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potable water (from a local public source) were available
ad libitum.
Observations were made, and data were collected as
described in Table 1.
Results were analyzed using analysis of variance
(ANOVA) as a completely randomized design by the
generalized linear model (GLM) of SAS v.8 (SAS, 1999-
2001). Statistical significance was declared at p 0.05, and
0.05  p  0.10 was considered a near-significant trend.
Performance variables were analyzed as a block design
with the four treatments and two sexes in a factorial
arrangement and three blocks (tier location). The individual
cage with four male or four female chickens (at the begin-
ning of the trial) was the replicate unit for statistical pur-
poses. Results from hematological and blood biochemical
variables (1 bird per cage from 10 male cages and 10
female cages per treatment) were analyzed as a factorial
design with four treatments and two sexes as the main
factors and one bird as the replicate unit. Data were ana-
lyzed to detect possible outliers; a value was considered an
outlier if it was outside the range defined by (treatment
mean)+ (3  pooled Standard Error of the Mean [SEM]).
Results from microbiological counts below the limit of
detection (absence) were assigned the half value of this
limit and analyzed by a nonparametric test.
Piglet tolerance study, CCL-329-03-V-OO
Seventy-two healthy, mixed-sex, weaned piglets aged
28 days (Topigs Tempo boar  Topigs 20 sow) were
selected from a single batch of piglets (eight litters born
within a single week). Piglets were randomly assigned to
the experimental treatments on the basis of body weight
(BW), gender, and ancestry such that each treatment group
was balanced at the start of the trial.
This study was conducted at the Laverdonk Research
Farm (Heeswijk-Dinther, The Netherlands). Three identi-
cal nursery units with six pens each (four piglets per pen)
were used simultaneously for this study. The housing con-
ditions used were typical for pig husbandry in the trial
location and followed Dutch IKB farm standards. Piglets
were housed in pens measuring 2.60  1.20 m2 (area
3.12 m2). The floor in the pens was a fully slatted, plastic
floor. Computer-controlled heating and mechanical venti-
lation systems were used to ensure similar climatic condi-
tions between nursery units. Temperature at the onset of the
study was set to 28C, and temperature was decreased gra-
dually to 22C by week 5. Any effects of nursery unit on
performance and health traits were considered absent or
negligible, due to the use of similar housing conditions,
climate control systems, and simultaneous testing.
To avoid cross-contamination with the microbial addi-
tive between pens of different treatments, each experimen-
tal treatment was assigned to pens within a single unit.
Control piglets were fed, handled, and weighed first, and
attendants changed boots and overalls before handling ani-
mals receiving CBM 588. Each type of feed (control, low
dose, high dose) was identified by the addition of an inert
color marker (red, blue, yellow) to prevent incorrect test
article administration.
All diets were formulated without antibiotics and met or
exceeded nutrient requirements recommended by the Dutch
Centraal Veevoeder Bureau for piglet nutrition and the nutri-
ent requirements of the National Research Council (NRC).27
Piglets had access to a commercial creep feed during nur-
sing. From weaning (day 0) until day 13, prestarter feed was
provided. On day 14, a mixture of 50% prestarter and 50%
starter feed was provided, followed by starter feed only from
day 15 onward. All diets were presented as meal (not pel-
leted) and provided ad libitum. Potable water (from a local
public source) was also provided ad libitum. Composition of
the diets is detailed in Supplementary Table 2.
There were three treatment groups: control (basal
diet, no CBM 588), basal diet þ CBM 588 5  105 CFU/
g feed, and basal diet þ CBM 588 5  107 CFU/g feed
(n¼ 24/group). CBM 588 was added to the diets in place of
starch. Feed samples were tested at manufacture and after
14 and 42 days to verify CBM 588 content.
Observations were made, and data were collected as
described in Table 2.
Zootechnical performance data were analyzed by
ANOVA (using Genstat software, VSNi, UK) corrected with
Tukey’s method. The pen within a unit was incorporated as
block factor (i.e. pen 1 within units 1, 2, and 3 is block 1; pen
2 within units 1, 2, and 3 is block 2; etc.). In addition, the
following linear contrasts were analyzed: T1 versus T2, T1
versus T3, and T2 versus T3. The following model was used
Table 1. Detailed observations for broiler tolerance study.
Parameter Day
Cage body weight Days 1, 21, and 42
Cage feed intake Days 1, 21, and 42
Fecal samples Days 21 and 42 (two cages per treatment
group)
General health Daily record (e.g. diarrhea, respiratory
problems, leg problems, etc.)
Mortality/culls Recorded as they occurred, including the
weight of dead birds and the most
probable cause of mortality
Blood samples Taken from 10 male and 10 female broilers
per treatment at the end of the trial (day
43), and subject to routine hematology and
blood biochemistry
Zootechnical
performance
Cage weight gain, feed intake, and feed
conversion ratio (mortality-corrected
feed: gain) were calculated for days 1–21,
days 21–42, and days 1–42. European
production efficiency factors were
calculated at day 42
Adverse events Recorded as necessary (e.g. abrupt weather
changes, disease outbreaks, power failures,
feed/water blockages, frozen/burst pipes,
etc.).
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yij ¼  þ Ai þ Bj þ eijk
where y represents the response variable, m represents over-
all mean, A represents pen within a unit, B represents treat-
ment, and e represents error. The 2 procedure was used for
the number of culled or lost animals and number of treat-
ment animals. An ordinal regression analysis, following the
McGullagh threshold model, was used to analyze the fecal
scores. Significance was defined as probability p  0.05,
with 0.05 < p  0.10 considered a near-significant trend.
Turkey tolerance study, MGT01/2011
Eight-hundred female day-old turkeys (Big 7) were pur-
chased from a local commercial source. Birds were not
routinely vaccinated. The study was conducted according
to the principles set out in the relevant parts of Commission
Regulation (EC) no. 429/2008 of April 25, 2008 on detailed
rules for the implementation of Regulation (EC) no 1831/
2003 of the European Parliament and of the Council as
regards the preparation and the presentation of applications
and the assessment and the authorization of feed additives.
The trial was conducted by the Department of Poultry
Science, Olsztyn University of Warmia and Mazury, Olsz-
tyn, Warmian-Masurian Voivodeship, Poland. Turkeys
were housed in a clean, disinfected room on fresh wood
shavings. Birds were randomly distributed into 32 floor
pens, each containing 25 turkeys. Pens of different treat-
ment groups were divided by physical barriers to avoid
cross-contamination. Control animals were handled first,
and attendants changed gloves and boot covers before han-
dling animals receiving CBM 588.
Feeds met or exceeded nutritional requirements for tur-
keys according to NRC guidance.28 Diets were formulated
without probiotics (other than CBM 588 as indicated),
enzymes, coccidiostats, veterinary antibiotics, or antibiotic
alternatives (e.g. organic acids/salts, high copper/zinc,
etc.). All nutrients were supplied in normal concentrations
(i.e. to meet nutritional needs, not exceeding EU maximum
permitted concentrations). Starter feed was provided during
weeks 1–4, grower feed during weeks 5–8, and finisher
feed during weeks 9–12. Diets were fed ad libitum in meal
form. Potable water (from a local public source) was also
available ad libitum. The composition of all diets is detailed
in Supplementary Table 3.
There were four dietary treatment groups: control (basal
diet, no CBM 588), basal dietþ CBM 588 1.25 105 CFU/
g, basal dietþ CBM 588 2.5 105 CFU/g, and basal dietþ
CBM 588 2.5  107 CFU/g. Feeds containing CBM 588
Table 2. Detailed observations for piglet tolerance study.
Parameter Day
Individual body
weight
Days 1 (one day before weaning), 14, and 42
Pen body weight Day 0 (day of weaning)
Pen feed intake Days 0–14 (pre-starter phase) and 14–42
(starter phase)
Feed change Day 14
Pen feed/fecal
samples
Days 14 and 42
Health Daily record trial log book of each pen
Mortality/culls Recorded, including the reason for culling and
the most probable cause of mortality. For
common postweaning problems such as
diarrhea and respiratory disease, the cause
was determined by an experienced animal
attendant. When the cause of mortality
was unclear, a veterinary postmortem was
carried out as soon as possible after death
Fecal score 3  per week, by judging per pen the number
of pigs within a category of fecal
consistency: 1 ¼ firm, 2 ¼ soft feces, and
3 ¼ watery feces, severe diarrhea
Condition score 3  per week, by judging per pen the number
of pigs within a category of condition score
(long hair, body condition, color): 1 ¼ good
condition¼ > full belly, sleek hair, good pink
color, 2 ¼ middling condition ¼ > in
between, and 3 ¼ bad condition ¼ > skinny,
long hair, pale color
Zootechnical
performance
Pen weight gain, feed intake, and feed efficiency
(feed: gain) were calculated for the periods:
days 0–14, 14–42, and 0–42. When any
piglet was removed from the study for any
reason, it was weighed and all the remaining
feed in the trough was weighed.
Corrections were made for animals
removed from the study by calculating both
feed intake and weight gain only for the true
animal days present per period
Adverse events Recorded as necessary (e.g. power failure,
feed/water failures, disease outbreak, etc.)
Table 3. Detailed observations for turkey tolerance study.
Parameter Day
Individual body
weight
Days 1, 28, 42, 56, and 84
Pen body weight Days 28, 42, 56, and 84
Pen feed intake Days 28, 42, 56, and 84
Pen fecal samples Weeks 4, 8, and 12 (1 pen/treatment)
Health Daily
Mortality/culls Recorded as they occurred, including the
weight of dead birds and the most
probable cause of mortality
Blood samples Taken on day 42 (10 birds/treatment) for
routine hematology and biochemical
measurements
Zootechnical
performance
Pen growth, weight gain, feed intake, and feed
efficiency (feed conversion ratio,
mortality-corrected feed: gain) were
calculated for the periods: days 0–28, days
29–42, days 43–56, and days 57–84
Adverse events Recorded as necessary (e.g. power failure,
storms, feed/water blockages, disease
outbreak, etc.)
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were prepared after the control feed to prevent cross-
contamination. All diets were calculated to be isonutritive.
Feed samples were tested at manufacture and after 21, 42,
and 84 days to verify CBM 588 content and homogeneity
of mixing in feeds.
Observations were made, and data were collected as
described in Table 3.
Zootechnical performance data were analyzed by
ANOVA, with the pen as the experimental unit. The
applied experimental model was a randomized complete
block design of four treatments allocated into eight blocks.
Probability was obtained from the F value in the ANOVA
table. Significance was declared at p  0.05, with 0.05 < p
0.10 considered a near-significant trend. The GLM pro-
cedure of Statistica for Windows, version 9.0, was used.
ANOVA was also used to analyze mortality/culls and
hematology/biochemical parameters, with treatment as the
basic experimental unit.
Results
Organic acid production
To confirm that CMB 588 generates high levels of butyrate,
the production of organic acids by a variety of bacteria
known to produce SCFA was compared. C. butyricum
CBM 588, C. butyricum ATCC19398T, Bifidobacterium
adolescentis JCM1275T, Bifidobacterium bifidum
JCM1209, Bifidobacterium breve JCM1192T, Bifidobac-
terium infantis JCM1222T, Bifidobacterium longum
JCM1217T, Enterococcus faecium JCM5804T, Enterococ-
cus faecalis JCM5803T, Lactobacillus casei JCM1134T,
Lactobacillus plantarum JCM1149T, and Lactobacillus
acidophilus JCM1132T were analyzed for their ability to
produce acetate, propionate, butyrate, SCFA (total), succi-
nate, and lactate. The results of this analysis are presented
in Table 4. While all tested species produced notable
amounts of SCFA, only CBM 588 and C. butyricum
ATCC19398T produced detectable amounts of butyrate.
For both strains, butyrate represented approximately 40%
of the total SCFA generated.
Broiler tolerance study
Feed analysis confirmed proper nutrient content of all
study diets, and the nutrient content was similar for all
treatments. The analyzed counts of CBM 588 in feeds
were in line with target values for all treatments (see
Supplementary Table 4). Fecal samples were analyzed for
the presence of CBM 588 and showed a dose-dependent
increase in CBM 588 counts at both day 21 (1.70 (below
the limit of detection), 2.23, 3.79, and 5.29 log10 CFU/g)
and day 42 (2.00, 3.17, 3.39, and 5.46 log10 CFU/g). These
data confirmed exposure of birds to CBM 588 as intended
by the study design.
Zootechnical performance data over the entire study
period (42 days) are summarized in Table 5. Signifi-
cant differences were detected between treatments
within the first period of the trial (days 1–21). Birds
from T4 had a lower average daily feed intake (ADFI)
than other groups. As BW and average daily gain
(ADG) were not significantly different, the lower ADFI
was a consequence of improved (near-significant, p ¼
0.056) feed conversion ratio (FCR, mortality-corrected
feed: gain). Similarly, in the second period of trial
(days 21–42), birds from T2 had a significantly lower
ADFI than other groups; this again led to significantly
improved FCR. Significant differences were also
detected for ADG during this second period, with T3
significantly lower than T1 and T2. Over the whole
trial period (days 1–42), no significant differences were
detected between treatments for final BW, ADG, and
ADFI. FCR was significantly improved for T2 birds
compared to T1 and T3.
No significant differences were detected in mortality
between groups, and the overall incidence of mortality was
Table 4. Production of short-chain fatty acids, succinate and lactate concentrations by Clostridium butyricum, lactic acid bacteria, and
bifidobacterial.a
Strain Acetate Propionate Butyrate SCFA Succinate Lactate
Clostridium butyricum CBM 588 19.1+ 0.3 4.3 + 0.7 15.1+ 0.8 38.5+ 1.4 1.5+ 0.3 9.3 + 0.8
Clostridium butyricum ATCC19398T 24.8+ 1.0 7.7 + 0.3 21.5+ 1.3 54.0+ 0.6 2.2+ 0.2 11.2 + 1.2
Bifidobacterium adolescentis JCM1275T 37.9+ 1.3 7.2 + 0.3 N.D. 45.1+ 1.6 2.9+ 0.1 14.1 + 2.1
Bifidobacterium bifidum JCM1209 37.1+ 0.9 7.3 + 0.2 N.D. 44.4+ 1.1 2.7+ 0.1 3.0 + 0.1
Bifidobacterium breve JCM1192T 48.6+ 2.4 6.4 + 0.1 N.D. 55.0+ 2.4 2.9+ 0.1 15.9 + 0.5
Bifidobacterium infantis JCM1222T 34.7+ 0.9 7.2 + 0.2 N.D. 41.9+ 1.0 2.7+ 0.3 1.7 + 0.3
Bifidobacterium longum JCM1217T 38.6+ 1.3 7.4 + 0.3 N.D. 46.0+ 1.6 3.2+ 0.3 13.4 + 1.4
Enterococcus faecium JCM5804T 5.9+ 0.5 8.7 + 0.5 N.D. 14.6+ 0.9 2.3+ 0.1 37.7 + 2.4
Enterococcus faecalis JCM5803T 10.8+ 0.3 10.2 + 0.3 N.D. 21.0+ 0.6 2.4+ 0.0 46.2 + 1.2
Lactobacillus casei JCM1134T 4.8+ 0.1 7.0 + 0.0 N.D. 11.8+ 0.1 2.1+ 0.0 32.8 + 0.3
Lactobacillus plantarum JCM1149T 8.9+ 0.5 6.9 + 0.5 N.D. 15.8+ 1.0 4.0+ 0.2 41.9 + 3.5
Lactobacillus acidophilus JCM1132T 4.1+ 0.2 6.9 + 0.2 N.D. 10.9+ 0.3 4.9+ 0.2 32.9 + 0.6
SCFA: short-chain fatty acids (total); CBM 588: C. butyricum MIYAIRI 588; N.D.: not detected.
aValues are presented in mmol/mL.
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low at less than 2%. No deaths were attributed to the pres-
ence of CBM 588 in the feed.
Results from hematological and biochemical analyses of
blood samples taken on day 43 are presented in Table 6. No
significant differences were detected between groups for
any of the variables studied. Moreover, values were similar
between treatments.
Piglet tolerance study
Feed analysis confirmed proper nutrient content of all pig-
let study diets, and the nutrient content was similar for all
groups. The detected counts of CBM 588 in feeds were in
line with target values for all treatments (see Supplemen-
tary Table 5). CBM 588 counts in fecal samples from
Table 5. Zootechnical performance of broilers.
T1 T2 T3 T4
Treatment Control 5  105 CFU/g 5  106 CFU/g 5  107 CFU/g
Days 0–21
BW, day 0 (g) 44.9 + 0.9 44.9+ 0.9 44.9+ 0.9 45.1+ 0.2
BW, day 21 (g) 652 + 60 670+ 80 682 + 61 664 + 61
ADG (g) 28.9 29.8 30.4 29.5
ADFI (g) 43.1b 43.3b 44.4b 40.9c
FCR 1.509A 1.463A 1.467A 1.390B
EPEF 197 204 209 213
% dead/culled 0 0 1 0
Days 21–42
BW, day 42 (g) 1741 + 174 1739+ 192 1707 + 157 1718 + 128
ADG (g) 54.4b 54.0b 51.0b 52.9bc
ADFI (g) 97.6b 92.3c 94.1bc 96.9b
FCR 1.805b 1.711c 1.854b 1.835b
EPEFa 306bc 317b 272c 286bc
% dead/culleda 0.1 0.1 2.2 1.7
Days 0–42
ADG (g) 41.8 41.7 40.7 41.1
ADFI (g) 70.5 67.6 69.3 68.6
FCR 1.688b 1.621c 1.705b 1.671bc
EPEFa 249bc 255b 235c 242bc
% dead/culleda 0 1 2.1 1.6
BW: body weight; ADG: average daily gain; ADFI: average daily food intake; FCR: feed conversion ratio; EPEF: European production efficiency factor.
aAt day 28, a water blockage affected some cages of the lower tier of females; as a consequence, 1 female of T2, 3 females of T3, and 4 females of T4 died;
these mortality data were not included in the analysis and the results presented in this table. Different superscripts denote differences at bcp  0.05 and
ABp  0.01. n ¼ 12/sex/group.
Table 6. Hematological and biochemical analyses of blood samples taken from broilers on day 43.a
T1 T2 T3 T4
Control 5  105 CFU/g 5  106 CFU/g 5  107 CFU/g
MCHC (g/dL) 31.2+ 0.7 31.4+ 0.6 31.4+ 0.6 31.4+ 0.8
HB (g/dL) 11.0+ 0.9 11.1+ 0.9 11.3+ 0.9 11.0+ 0.9
HT (%) 35.2+ 2.7 35.3+ 2.6 35.9+ 2.7 35.1+ 2.9
Leukocytes, (103 cells/mL) 7.75+ 1.07 7.6+ 1.05 7.8+ 1.15 8.15+ 1.14
Heterophils (%) 77.1+ 4.76 75.8+ 6.53 76.8+ 5.01 78.5+ 3.93
Eosinophils (%) 0.2+ 0.5 0.25+ 0.6 0.15+ 0.5 0.25+ 0.6
Basophils (% 3.1+ 2.4 2.5+ 2.0 3.4+ 2.0 1.9+ 1.9
Lymphocytes (%) 16.8+ 4.6 18.7+ 7 16.9+ 4.3 15.9+ 3.1
Monocytes (%) 3.0+ 2.3 2.8+ 1.3 2.8+ 1.3 3.6+ 1.8
ALT (U/L) 3.55+ 1.99 3.30+ 0.92 3.25+ 0.72 2.95+ 0.39
AST (U/L) 478 + 522 326 + 199 287+ 41 276+ 50
GGT (U/L) 30.7+ 6.1 29.0+ 5.3 28.6+ 4.9 29.9+ 6.2
PROT (g/L) 32.9+ 3.23 32.9+ 2.25 33.2+ 2.39 32.2+ 2.26
ALB (g/L) 12.2+ 1.2 12.5+ 0.8 12.5+ 1 12.1+ 1.1
URIC (mg/dL) 5+ 1.4 6+ 1.7 5+ 2.0 5+ 1.4
MCHC: mean corpuscular hemoglobin concentration; HB: hemoglobin; HT: hematocrit; ALT: alanine aminotransferase; AST: aspartate amino transfer-
ase; GGT: gamma glutamine transpeptidase; PROT: total protein; ALB: albumin; URIC: uric acid.
an ¼ 20/sex/group. Each bird was considered a replicate; no significant differences were detected between groups for any of the variables studied.
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control pens at both 21 and 42 days were below the limit of
detection (<4.0 log10 CFU/g). Treated groups displayed
dose-dependent increases in CBM 588 counts at both 21
days (4.4–4.5 and 5.4 log10 CFU/g for T2 and T3, respec-
tively) and 42 days (4.3–4.4 and 5.0–5.1 log10 CFU/g,
respectively). These data confirmed the exposure of piglets
to CBM 588 as intended by the study design. Fecal con-
sistency was good (average score at or near 1.00) through-
out the study, and no significant differences were observed
between groups (data are not shown).
The addition of CBM 588 at both a low (5 105 CFU/g)
and high (5  107 CFU/g) dose did not affect zootechnical
performance in weaned piglets (Table 7). ADG and FCR
were considered good by current Dutch standards.
One piglet in the high-dose group was treated twice with
antibiotics due to poor zootechnical performance, most
likely associated with porcine ileitis (Lawsonia intracellu-
laris) and unrelated to treatment with CBM 588. No mor-
talities occurred in any group during the study.
Turkey tolerance study
Feed analysis confirmed proper nutrient content of all
turkey experimental diets, and the nutrient content was
similar for all treatments. CBM 588 was below the limit
of detection in the control feed and in line with target
values for all treatment-containing feeds (see Supplemen-
tary Table 6). Fecal samples displayed dose-dependent
increases in CBM 588 counts at 28 days (2.43, 4.15,
5.99, and 4.79 log10 CFU/g for T1, T2, T3, and T4, respec-
tively), 56 days (2.41, 4.26, 4.04, and 4.86 log10 CFU/g),
and 84 days (3.67, 5.34, 6.04, and 6.92 log10 CFU/g).
These results confirmed exposure of the birds to CBM
588 as intended by the study design.
Zootechnical performance data for turkeys receiving
CBM 588 are presented in Table 8. Although there were
no statistically significant differences between treatments
in BW gain during the first study period (days 0–28), T4
birds reached the highest BW in comparison with the other
treatments. The same effect was observed during the
second and third experimental periods (days 29–42 and
43–56). During the fourth study period (days 57–84), T4
birds had significantly higher weight gain compared to T1.
At day 84, T4 birds weighed significantly more than T1
birds. Additionally, the weight of T3 birds trended higher
than the T1 control group (p ¼ 0.063).
Over the entire study period (days 0–84), birds from all
treated groups (T2–T4) had improved weight gain com-
pared to the T1 control group, but differences were only
significant for T4. T3 birds showed a trend toward
improved weight gain compared to T1 control birds
(p ¼ 0.062).
No significant differences were observed in feed intake
between treatments. Overall, birds in groups T3 and T4
consumed more feed than birds fed the T1 control diet.
During the first (days 0–28), second (days 29–42), and
third (days 43–56) study periods, no significant differences
in FCR were observed between treatments. Over the entire
study period (days 0–84), T2 birds had significantly better
FCR compared to the T1 control group. Additionally,
FCR for T4 birds showed a trend toward improvement
(p ¼ 0.090) versus T1 control birds.
Global mortality for this study was relatively low at 1.5,
5.5, 3.5, and 3.5% for groups T1–T4, respectively. Mortal-
ities and culls were due to cachexia, weak legs, enlarged
crop, and sudden death syndrome. No significant differ-
ences between groups were observed.
Results from hematological and biochemical analyses of
blood samples taken on day 42 are presented in Table 9. No
significant differences were detected between groups for
any of the variables studied. Moreover, values were
numerically similar between groups.
Discussion
CBM 588 has been approved in the EU as a feed additive
for turkeys and chickens for fattening, chickens reared for
laying, weaned piglets, minor avian and weaned porcine
species, and as a novel food ingredient for humans. The
studies presented in this article investigated the safety and
tolerance of CBM 588 in broilers and weaned piglets at
doses up to 100 the maximum EU recommended dose
of 5  105 CFU/g feed, and in turkeys at doses up to
200 the maximum EU recommended dose of 1.25 
105 CFU/g feed.
Over a trial period of 42 days, broilers receiving control
diet or diet containing 5  105, 5  106, or 5  107 CFU
CBM 588/g feed showed no significant differences in zoo-
technical performance parameters, including final BW,
ADG, and ADFI. FCR was significantly improved for T2
Table 7. Zootechnical performance of piglets.a
T1 T2 T3
Control 5  105 CFU/g 5  107 CFU/g
Days 0–14
BW, day 1 (kg) 8.1+ 0.34 8.1+ 0.34 8.1+ 0.3
BW, day 14 (kg) 11.4+ 1.46 11.3+ 1.48 11.1 + 1.14
ADG (g/day) 225 227 210
ADFI (g/day) 327 315 301
FCR 1.47 1.42 1.45
Days 14–42
BW, day 42 (kg) 32.3+ 3.19 31.6+ 2.98 31.2 + 2.38
ADG (g/day) 747 724 719
ADFI (g/day) 1208 1163 1127
FCR 1.62 1.61 1.57
Days 0–42
ADG (g/day) 573 558 549
ADFI (g/day) 914 880 852
FCR 1.6 1.58 1.55
BW: body weight; ADG: average daily gain; ADFI: average daily food
intake; FCR: feed conversion ratio.
aNo significant differences were seen between groups in any parameter.
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compared to T1 control birds. No differences were
observed in natural mortality, which was less than 2%, and
no deaths were attributed to the presence of CBM 588 in the
feed. Hematological and biochemical data were not
affected by exposure to CBM 588. Therefore, CBM 588
was well-tolerated by broiler chickens at up to 100 the
maximum recommended dose, and the inclusion of CBM
588 in the diet did not present any safety concerns. More-
over, some performance variables (ADG and FCR from
days 1 to 21) were significantly improved at the highest
dose (5  107 CFU/g).
In the piglet tolerance study, the inclusion of CBM 588
in the diet at 5 105 or 5  107 CFU/g feed had no effects
on zootechnical performance. No piglets died during the
study, and only one animal was treated with antibiotics
due to poor condition, most likely associated with porcine
ileitis (Lawsonia intracellularis) and unrelated to
CBM588. Hence, CBM 588 was shown to be safe and
well-tolerated in piglets at up to 100 the EU recom-
mended dose.
The inclusion of CBM 588 in the diet of turkeys at
1.25  105, 2.5  105, or 2.5  107 CFU/g feed did not
negatively affect zootechnical performance, blood hema-
tology, or biochemical parameters. Some performance
variables were improved by CBM 588, which produced
dose-dependent increases in final BW (day 84) and overall
ADG (days 0–84). These results confirm that CBM 588 is
safe and well-tolerated in turkeys at up to 200-fold of EU
recommended dose (2.5  107 CFU/g).
SCFAs, including butyrate, have been estimated to
contribute 20–30% of the caloric requirements for omni-
vorous or herbivorous, nonruminant animals.5 Across
commercial animal species, the supplementation of
butyrate has been shown to positively impact the devel-
opment of the gastrointestinal tract, often resulting in
notable increases in growth performance.15 As a pro-
ducer of butyrate, CBM 588 may provide additional
nutrition beyond that contained in standard feed formu-
lations. This possibility is supported by the current stud-
ies, in which CBM 588 administration had positive
Table 8. Zootechnical performance of turkeys.a
T1 T2 T3 T4
Control 1.25  105 CFU/g 2.5  105 CFU/g 2.5  107 CFU/g
Days 0–28
BW, day 0 (kg) 0.059+ 0.001 0.059 + 0.001 0.058 + 0.000 0.059+ 0.001
BW, day 28 (kg) 0.931+ 0.057 0.936 + 0.038 0.924 + 0.033 0.939+ 0.028
ADG (g/day) 31.1+ 2.0 31.3 + 1.3 30.9 + 1.2 31.4+ 1.0
ADFI (g/day) 53.8+ 3.6 52.8 + 2.9 53.3 + 2.2 54.0+ 2.1
FCR 1.733+ 0.070 1.694 + 0.045 1.725 + 0.032 1.723+ 0.068
% dead/culled 0.50 1.00 0 1.00
Days 29–42
BW, day 42b (kg) 1.848d + 0.031 1.892de + 0.042 1.881de + 0.039 1.903e + 0.052
ADG (g/day) 65.5+ 5.1 68.3 + 2.4 68.4 + 3.3 68.9+ 4.3
ADFI (g/day) 128.9+ 4.8 124.4 + 4.5 129.3 + 5.9 129.7+ 7.3
FCR 1.974+ 0.120 1.836 + 0.109 1.900 + 0.107 1.888+ 0.141
% dead/culled 0 1.00 0.50 0
Days 43–56
BW, day 56b (kg) 3.549+ 0.046 3.627 + 0.084 3.606 + 0.096 3.646+ 0.093
ADG (g/day) 121.5+ 4.2 123.9 + 7.1 123.2 + 7.6 124.5+ 6.7
ADFI (g/day) 250.2+ 9.2 243.0 + 9.1 251.4 + 11.5 252.2+ 14.2
FCR 2.060+ 0.092 1.984 + 0.083 2.043 + 0.142 2.021+ 0.078
% dead/culled 0.50 3.00 1.00 0.50
Days 57–84
BW, day 84 (kg) 6.978e + 0.179 7.116de + 0.174 7.149de + 0.166 7.274d + 0.153
ADG (g/day) 122.5e + 6.7 124.6de + 3.9 126.5de + 4.3 129.6d + 4.1
ADFI (g/day) 326.5+ 25.6 324.7 + 14.5 330.1 + 20.3 334.6+ 12.9
FCR 2.677+ 0.102 2.607 + 0.079 2.616 + 0.120 2.604+ 0.059
% dead/culled 0.50 0.50 1.50 2.00
Days 0–84
ADG (g/day) 82.4e + 2.1 84.0de + 2.1 84.4de + 2.0 85.9d + 1.8
ADFI (g/day) 190.4+ 9.9 187.9 + 6.6 193.1 + 9.8 195.0+ 6.3
FCRc 2.309d + 0.068 2.231e + 0.048 2.266de + 0.081 2.253de + 0.039
% dead/culled 1.50 5.50 3.50 3.50
BW: body weight; ADG: average daily gain; ADFI: average daily food intake; FCR: feed conversion ratio.
aDifferent superscripts denote differences between columns at dep  0.05; n ¼ 200/group (8 replicates of 25 birds/treatment).
bOverall p-value indicates a trend (0.05 < p  0.10), but comparison test (Duncan) indicates a significant difference between T1 and T4.
cOverall p-value indicates a trend (0.05 < p  0.10), but comparison test (Duncan) indicates a significant difference between T1 and T2.
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effects on certain zootechnical performance parameters,
particularly for broilers and turkeys.
Overall, CBM 588 administered in feed at doses up to
5  107 CFU/g (chickens and piglets) or 2.5  107
CFU/g (turkeys) was shown to be safe and well-
tolerated in all animals. As a source of butyrate, CBM
588 enhances the nutritional value of commercial feeds
without safety concerns.
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